Side-by-side · Research reference

SNAP-8vsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED8/46 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

SNAP-8

Synthetic Octapeptide · Cosmetic Topical

TopicalRoute

8-AAPeptide length

SNAREPrimary target

Topical · Facial application · Twice daily

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

SNAP-8

Vesugen

Primary target

SNARE complex (SNAP-25 competitive binding site)

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

N/A — topical cosmetic, no systemic endocrine axis

Not applicable — does not operate via hormone axis

Origin

Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

SNAP-8

Vesugen

Typical concentration

2–10% in cosmetic formulationsLupin 2024 Raikou 2017

Commercial products typically use 5–10%.

—

Application frequency

Twice daily (morning and evening)Lupin 2024

—

Treatment duration

20–60 days for visible effectRaikou 2017

Skin microtopography improvements measured at 20-day intervals.

—

Formulation type

Oil-in-water emulsion, serum, cream

—

Application site

Facial skin — glabellar lines, crow's feet, forehead

—

Evidence basis

RCT, in vitro skin penetration studies

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Onset of effect

Visible reduction in wrinkle depth by day 20–28Raikou 2017

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

Frequency

—

Not specified in available literature

Duration

—

Case series report treatment courses in elderly arterial insufficiency

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

03Metabolic / Fat Loss Evidence

04Side Effects & Safety

Parameter

SNAP-8

Vesugen

Cytotoxicity

Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)

Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.

—

Skin irritation

Minimal; well-tolerated in clinical use

—

Peptide oxidation

Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021

Formulation stability issue, not a direct adverse effect.

—

Systemic absorption

Negligible; peptide remains in stratum corneum and epidermisKraeling 2015

—

Hypersensitivity

Rare; no widespread allergic reactions reported

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

SNAP-8

·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients

Vesugen

—

Relative Contraindications

SNAP-8

·Active skin infections or open wounds at application site
·Neuromuscular disorders (theoretical concern, no documented cases)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

SNAP-8

Vesugen

1. Cleansing

Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Application

Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Frequency

Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Layering

Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Storage

Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.

—

6. Duration

Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.

—

06Stack Synergy

SNAP-8

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)